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A FUNCTIONAL POLYMORPHISM IN THE CATECHOL-O
METHYLTRANSFERASE (COMT) GENE IS ASSOCIATED
WITH OA-RELATED PAIN
J.B. van Meurs, A.G. Uitterlinden, L. Stolk, H.A. Pols,
S.M. Bierma-Zeinstra
Erasmus MC, Rotterdam, The Netherlands
Purpose: Joint complaints are very common in the elderly and
a major reason for disability and reduced quality of life. It is
clear that radiographic evidence of joint damage predisposes to
joint pain, but the severity of the joint damage is only weakly
related to the severity of the pain experienced. Whether a person
develops chronic pain or not in a (radiographically) damaged
joint is partly determined by genetic variations and heritability
estimates for joint pain range between 35-65%. Thus, persons
that develop chronic pain might possess a combination of genetic
variations that increase their sensitivity to pain. The COMT-gene
(catechol-O-methyltransferase) is involved in pain perception;
inhibition of COMT was shown to increase pain sensitivity. The
aim of our study was to examine whether a well-known functional
polymorphism in the COMT-gene (Val158Met) inﬂuences OA-
related pain.
Methods: We studied 3033 individuals aged 55 years and over
from a large population-based study (Rotterdam study). All sub-
jects were scored for radiographic hip OA (deﬁned as Kellgren&
Lawrence ≥2) as well as hip pain (assessed by interview). Geno-
types of the Val158Met polymorphism of the COMT-gene were
assessed by Taqman.
Results: Allele frequency of the low activity allele of the COMT
gene (158Met) was 55%. In the total population, the COMT
variant was not associated with hip pain. However, when we
selected individuals who had radiographically deﬁned hip-OA (n
=288), we observed that carriers of the 158-Met variant had
2.7 times higher risk (95% CI: 1.2-6.1; p=0.02) for hip pain as
compared to the ValVal-genotype. This effect was fully driven
by the women (n =171). Female carriers of the 158-Val allele
were 4.9 times more likely to have pain (95% CI: 1.6-14.8;
p=0.005) while radiographical damage to the hip was present
in both genotype groups. These results were not affected by
adjustments for age and BMI, two well known risk factors for OA.
Conclusions: The low activity allele of the COMT-gene (158Met)
is associated with increased hip pain in individuals with radiologi-
cal damage of the hip. This ﬁnding is in line with previous studies
in mice which showed that inhibition of COMT increases pain
sensitivity, presumably via the β2/3 adrenergic pathways. Our
ﬁndings need to be replicated in other large study populations,
but might have important clinical implications, since the preva-
lence of the COMT low activity allele is very high. Our results
also highlight the importance of studying joint related pain as a
separate trait in genetic epidemiological studies.
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DIFFERENTIAL EXPRESSION OF CALCITONIN
GENE-RELATED PEPTIDE AND P2X3 IN JOINT-SPECIFIC
AFFERENT NEURONES, IN THE RAT
MONO-IODOACETATEMODEL OF DEGENERATIVE
JOINT DISEASE
S.P. Ivanavicius, A. Ball, R. Webster, S. Read, F. Murray
Astrazeneca, Respiratory and Inﬂammation Research Area,
Alderley Park, United Kingdom
Purpose: The purine receptor P2X3 is almost exclusively ex-
pressed on non-peptidergic afferent neurones, a subtype of noci-
ceptors normally absent from the rat knee joint. During the course
of some animal models of joint pain, P2X3-immunoreactivity
(IR) is increased in calcitonin gene-related peptide (CGRP)-
expressing neurones and has therefore been implicated in as-
sociated nociceptive pathways. In the mono-iodoacetate (MIA)
model of degenerative joint disease, which exhibits histopatho-
logical similarities to osteoarthritis (OA), CGRP-expression in-
creases in joint-speciﬁc afferent neurones. Thus, for the current
study we aimed to determine weather or not any changes in
CGRP-expressing joint afferents are associated with increased
expression of P2X3 in the lumbar (L)4 dorsal root ganglion (DRG)
at days 3 and 14 post-disease induction.
Methods: Male Wistar rats (180-200g) were anaesthetised and
given intra-articular (i.a.) injections of ﬂuoro-gold (FG; 2%, 5 ul)
to label joint afferent neurones. Seven days later (day 0) ani-
mals were anaesthetised and given i.a. injections of MIA (1mg
in 20ul) or saline (20ul) (n = 8 per group). Hind limb weight
bearing measurements were recorded at regular intervals prior
to and throughout the study using an incapacitance meter. On
days 3 and 14 post-MIA, animals were anaesthetised following
weight bearing, perfused transcardially with 4% paraformalde-
hyde and ipsilateral L4 DRG removed (n = 4 per group, per
time point). Serial sections (14 um) were cut and labelled using
primary antibodies, anti-CGRP and anti-P2X3 and secondary an-
tibodies, Alexa Fluor 488 and 594, respectively. Weight bearing
data is presented as a percentage ratio (ipsilateral/contralateral),
CGRP and P2X3-IR are expressed as the mean percentage co-
localization with FG-labelled cells (± SEM). Animal experiments
were carried out in accordance with the UK Animals (Scientiﬁc
Procedures) Act, 1986 and related guidelines.
Results: Ipsilateral hind limb weight bearing was signiﬁcantly
reduced in MIA treated animals as compared to saline controls
on days 3 and 14 (Student’s t-test, P <0.001 and P <0.01,
respectively). FG-CGRP co-localization in L4 DRG was signiﬁ-
cantly greater at day 3 in the MIA group compared to the saline
group, 65.9% (±2.9%) and 45.5% (±5.0%), respectively (Mann
Whitney U-test, P <0.05). At day 14 there was no signiﬁcant
difference in FG-CGRP co-localization between groups. No sig-
niﬁcant difference in FG-CGRP-P2X3 co-localization and total
CGRP-P2X3 co-localization was measured between groups in
L4 DRG at any time point.
Conclusions: We have identiﬁed increased CGRP-IR in joint-
speciﬁc afferents in L4 DRG at day 3, but not day 14, following
i.a. injection of MIA. The day 3 increase in CGRP-expression in
joint afferents is comparable to previous ﬁndings observed at day
28 in the same model. The return to baseline levels of CGRP
at day 14 may imply a biphasic expression proﬁle for CGRP in
joint afferents, in the MIA model. During the early stages of the
MIA model (day 3) there is an inﬂammatory component, which
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